KESTRA MEDICAL TECHNOLOGIES, LTD.
- Open
- 25.78
- Day high
- 27.84
- Day low
- 25.78
- Prev close
- 25.44
- Volume
- 285K
- Mkt cap
- $1.5B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 5.2
- P/S
- 17.7
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$927K over the last 3 months (0 open-market buys, 4 sales)
- 🏛Institutions accumulating (13F)
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) is a Healthcare company listed on NASDAQ. The stock is up 53% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 4 sales (SEC Form 4).
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
KMTS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Mar 17, 2026 | $-0.60 | $-0.61 | -2.3% | $25M | -7.3% |
| Dec 11, 2025 | $-0.56 | $-0.62 | -10.7% | $23M | -1.3% |
| Sep 11, 2025 | $-0.66 | $-0.46 | +30.3% | $19M | -6.5% |
| Apr 17, 2025 | — | $-0.43 | — | $15M | — |
| Apr 30, 2024 | — | $-0.45 | — | $10M | — |
| Jan 31, 2024 | — | $-0.44 | — | $8M | — |
| Jul 31, 2021 | — | $-0.27 | — | — | — |
KMTS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 17, 2026 | Webster Brian Danieldirector, officer: See Remarks | Sell | 15,000 | $20.81 |
| Jun 4, 2026 | Moran Timothy P.officer: Chief Business Officer | Grant | 22,704 | — |
| Jun 4, 2026 | Webster Brian Danieldirector, officer: See Remarks | Grant | 75,681 | — |
| Jun 4, 2026 | Umberger Traci Sdirector, officer: See Remarks | Grant | 25,227 | — |
| Jun 4, 2026 | Mahboob Vaseemofficer: Chief Financial Officer | Grant | 25,227 | — |
| Jun 4, 2026 | Ford Alfred J Jrofficer: Chief Commercial Officer | Grant | 25,227 | — |
| May 18, 2026 | Webster Brian Danieldirector, officer: See Remarks | Sell | 6,845 | $21.46 |
| May 18, 2026 | Webster Brian Danieldirector, officer: See Remarks | Sell | 8,155 | $20.53 |
| Apr 16, 2026 | Webster Brian Danieldirector, officer: See Remarks | Sell | 15,000 | $20.04 |
| Mar 30, 2026 | COHEN RAYMOND Wdirector | Buy | 10,000 | $19.98 |
| Mar 19, 2026 | Webster Brian Danieldirector, officer: See Remarks | Sell | 15,000 | $20.27 |
| Mar 12, 2026 | Reilly Kevin Cdirector | Grant | 8,300 | — |
| Feb 19, 2026 | Webster Brian Danieldirector, officer: See Remarks | Sell | 3,272 | $26.29 |
| Feb 19, 2026 | Webster Brian Danieldirector, officer: See Remarks | Sell | 93 | $27.18 |
| Feb 19, 2026 | Webster Brian Danieldirector, officer: See Remarks | Sell | 11,635 | $25.39 |
Source: KMTS SEC Form 4 filings, latest Jun 17, 2026. For informational purposes only — not investment advice.
See the full KMTS insider & 13F page →KESTRA MEDICAL TECHNOLOGIES, LTD. company profile
Overview
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) is a wearable medical device and digital healthcare company founded in 2014 and headquartered in Kirkland, Washington. The company went public in March 2025 and focuses on transforming patient outcomes in cardiovascular disease through innovative monitoring and therapeutic intervention technologies. Kestra specializes in developing connected medical devices that are designed to be intuitive and intelligent, with their primary focus on protecting patients at elevated risk of sudden cardiac arrest.
Business
Kestra operates in the medical device industry, specifically focusing on wearable cardioverter defibrillators (WCDs) and digital health solutions for cardiovascular care. The company's core offering is the ASSURE WCD, which is part of their broader Cardiac Recovery System platform. A wearable cardioverter defibrillator is a life-saving medical device worn by patients who are at temporary high risk of sudden cardiac arrest (SCA) but are not candidates for an implanted defibrillator. Sudden cardiac arrest occurs when the heart suddenly stops beating effectively, which can be fatal within minutes without immediate treatment. The ASSURE WCD continuously monitors the patient's heart rhythm and can automatically deliver a life-saving shock if a dangerous arrhythmia is detected, essentially serving as an external safety net for the heart. The Cardiac Recovery System platform integrates several components: 1. The wearable monitoring and therapeutic device itself, 2. Digital health solutions that enable remote patient monitoring, 3. Patient support services that help with device compliance and education, and 4. Provider engagement tools that allow healthcare professionals to monitor their patients remotely. This comprehensive approach distinguishes Kestra from traditional medical device companies by combining hardware, software, and services into a unified solution designed to improve patient outcomes and reduce healthcare costs.
Revenue model
Kestra generates revenue primarily through product sales of their ASSURE WCD devices and associated service fees for their digital health platform and patient support services. The company's customers are primarily healthcare providers, including hospitals, cardiology practices, and health systems, who prescribe the devices to patients at risk of sudden cardiac arrest. Insurance companies and Medicare typically reimburse the cost of WCD therapy, making the devices accessible to patients who need them. The business model faces several margin-influencing factors. Positive factors include the growing awareness of sudden cardiac arrest prevention, an aging population with increasing cardiovascular disease prevalence, and expanding insurance coverage for WCD therapy. The company benefits from recurring revenue streams through their digital health services and patient monitoring programs. However, margins can be pressured by several challenges: intense competition from established players like Zoll Medical (now part of Asahi Kasei), regulatory compliance costs associated with FDA approval processes, the need for continuous R&D investment to maintain technological competitiveness, and potential reimbursement changes from insurance providers. Additionally, the company must invest heavily in clinical evidence generation to demonstrate improved patient outcomes, which is essential for maintaining physician adoption and insurance coverage.
Competitive moat
Kestra's competitive moat appears relatively narrow in the current market landscape. The wearable cardioverter defibrillator market is dominated by established players, particularly Zoll Medical's LifeVest system, which has been the market leader for over a decade with extensive clinical data and established relationships with healthcare providers. Kestra's potential moat lies in their integrated digital health platform approach, which combines the physical device with comprehensive remote monitoring and patient support services. This holistic solution could create switching costs for healthcare providers who become accustomed to the integrated workflow and data analytics. The company's focus on making devices more intuitive and connected could also provide differentiation in patient compliance and outcomes. However, the moat faces significant challenges. The medical device industry has high regulatory barriers, but these protect all approved competitors equally. Large, established medical device companies have substantially more resources for R&D, clinical trials, and market penetration. Zoll's entrenched position with cardiologists and hospitals, combined with their extensive clinical evidence base, creates a formidable competitive advantage. Additionally, the relatively small addressable market for WCDs means that gaining meaningful market share requires displacing existing relationships rather than capturing organic growth, making market penetration particularly challenging for a newer entrant.
Risks & safety
Kestra's margin of safety appears concerning based on current financial metrics, reflecting the challenges of a recently public, loss-making medical device company. • Cash burn and solvency: The company burned $22.4 million in free cash flow in Q3 2024, with $54.4 million in cash and short-term investments. At current burn rates, this provides roughly 6-8 quarters of runway before additional financing is needed. • Debt and balance sheet: Total liabilities of $365.9 million significantly exceed total assets of $108.0 million, resulting in negative shareholders' equity. However, the current ratio of 1.81 indicates adequate short-term liquidity. • Valuation metrics: With negative EBITDA of $18.1 million and an EV/EBITDA of -14.86, traditional valuation metrics are not meaningful. The company trades at a market cap of approximately $1.06 billion against quarterly revenue of $15.1 million. • Other considerations: Revenue growth from $8.3 million in Q3 2023 to $15.1 million in Q3 2024 shows positive momentum, but the company remains deeply unprofitable with significant ongoing losses that exceed revenue in most periods.
Recent development
Based on the available financial data, Kestra has shown revenue growth acceleration over the past few years, with quarterly revenue increasing from approximately $8.3 million in Q3 2023 to $15.1 million in Q3 2024, representing roughly 82% year-over-year growth. Annual revenue grew from $7.6 million in 2022 to $27.8 million in 2023, indicating significant business expansion. The company completed its initial public offering in March 2025, which likely provided additional capital to fund operations and growth initiatives. This public market debut represents a major strategic milestone, giving Kestra access to public capital markets for future funding needs and increased visibility in the medical device sector. The financial trajectory shows the company is in a scaling phase, with revenue growth outpacing the previous year significantly, though losses remain substantial. The improvement in cash position from $8.2 million at the end of 2023 to $54.4 million in Q3 2024 suggests successful capital raising activities, likely in preparation for or as a result of the IPO process. However, the company continues to face the typical challenges of a growing medical device company, including substantial R&D expenses, regulatory costs, and market development investments that currently exceed revenue generation.
KMTS company profile · for informational purposes only — not investment advice.
Track KMTS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free